title: Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment.
abstract: Aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") is a relatively new bisphosphonate which has been shown to be effective for control of hypercalcemia due to a variety of causes. Renal impairment has been reported following the use of other bisphosphonates and pre-existing renal impairment has been regarded as a contraindication to the use of AHPrBP. We report the successful use of intravenous AHPrBP to control hypercalcemia in three patients with renal impairment, one of whom was dialysis-dependent. No significant side effects were noted; in particular, there was no further deterioration in renal function. Intravenous AHPrBP may be a safe and effective agent for the control of hypercalcemia in patients with renal impairment.
authors: Department of Endocrinology, Royal Brisbane Hospital, Herston, Queensland, Australia.
authors: A S
authors: AS
authors: Yap
authors: G I
authors: GI
authors: Hockings
authors: S J
authors: SJ
authors: Fleming
authors: F A
authors: FA
authors: Khafagi
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications*; D000328:Adult; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate; D010531:Peritoneal Dialysis, Continuous Ambulatory
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate